Daniel Levangie is an experienced executive with senior operating experience in the field of medical devices and in vitro diagnostics. Mr. Levangie is currently the Chairman and Chief Executive Officer of Cerevasc, Inc. and co-founder and Managing Partner of ATON Partners, LLC, a Boston based private investment and management consulting firm. Most recently, Mr. Levangie was Chief Executive Officer of Dune Medical Devices and co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013. Prior to that Mr. Levangie was Chief Executive Officer of Keystone Dental, Inc., a Warburg Pincus portfolio company involved in dental reconstruction technologies and Chairman of the Board of ev3.
Beginning in 1992 Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October of 2007. Those positions included Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division.
Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL.
Mr. Levangie resides in Boston, MA with his wife Joan, and is a member of the Board of Directors of Exact Sciences, Inc. and Dune Medical Devices, LTD. He previously served as Lead Director of Insulet Corporation and Director of Liposcience, Inc. Mr. Levangie, a graduate of the College of Pharmacy of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School.
Patrick Sullivan is an experienced executive with an outstanding track record in managing early stage medical device and diagnostics ventures through all phases of growth. He is currently Managing Partner of ATON Partners, LLC and is President & Chief Executive Officer of Insulet Corporation (PODD). Prior to these roles Mr. Sullivan served as Chairman & CEO of Constitutional Medical Investors from 2008 until its sale to Roche Diagnostics Hematology in July 2013. From 1991 through 2007 Mr. Sullivan served in a variety of senior executive positions with Cytyc Corporation including Chairman, President and Chief Executive Officer until the acquisition of Cytyc Corporation by Hologic Corporation in October of 2007. Prior to joining Cytyc, Mr. Sullivan was employed in several senior marketing positions by Abbott Laboratories, a diversified healthcare company, and was a consultant with McKinsey & Company, an international management-consulting firm. Mr. Sullivan holds a Bachelor of Science degree, with Distinction, from the United States Naval Academy and a Master of Business Administration degree, with Distinction, from Harvard Business School. Mr. Sullivan is a Director of CereVasc, Perkin-Elmer Corporation and Theragenics Corporation.
Aaron Levangie manages all day-to-day aspects of the eShunt System development and commercialization program. He has served as CereVasc’s General Manager and General Counsel since the Company’s inception in July 2014. Before forming CereVasc, Mr. Levangie was Senior Vice President and General Counsel at Constitution Medical, Inc. (CMI); after Roche Diagnostics acquired CMI in 2013, he continued as a consultant to Roche supporting various post-merger integration initiatives. Before joining CMI Mr. Levangie was associated with two national law firms where he focused primarily on patent litigation matters before the U.S. International Trade Commission (ITC) and federal district courts. Mr. Levangie served as the Attorney Advisor to the Honorable Paul J. Luckern at the ITC before entering private practice where he supported Judge Luckern in managing more than 20 patent and trademark-based Section 337 investigations. He is admitted to practice in Massachusetts and before the U.S. Patent & Trademark Office.
Carl Heilman MD, is the Neurosurgeon-in-Chief at Tufts Medical Center. He is Chairman of the Department of Neurosurgery as well as a Professor at Tufts University School of Medicine. Internationally known for neurosurgical excellence, Dr. Heilman is the past president of the Boston Society of Neurology and Psychiatry, the New England Neurosurgical Society, the Society of University Neurosurgeons, and the North American Skull Base Society. He is currently one of the 14 Directors of the American Board of Neurological Surgeons.
Neurosurgeon Adel Malek, MD, PhD, heads the Cerebrovascular and Endovascular Division in the Department of Neurosurgery at Tufts Medical Center. Dr. Malek completed neurosurgical training at Brigham and Women’s/Children’s Hospital Boston and neurointerventional radiology fellowship at the University of California, San Francisco. Dr. Malek’s clinical expertise includes the multi-modal and minimally invasive treatment of brain aneurysms, arteriovenous malformations (AVMs) and dural arteriovenous fistulas (DAVFs). His research interest lies in the cellular biology, mechanotransduction, and fluid mechanics involved in the development of brain aneurysms and AVMs.
Mark Licari brings a wealth of manufacturing experience to CereVasc. Mark joins us from Insulet Corporation where he served as Vice President of Manufacturing Operations. While at Insulet he upgraded the company’s global supply chain and manufacturing effort during a period of rapid growth. Prior to Insulet Mark held similar roles at Novocure, Roche Diagnostics, and Cytyc Corporation. Mark also held engineering roles at Cytyc, Injectronics, HP, Millipore, and DEKA. Mark earned his B.S. in Plastics Engineering from University of Lowell.
Leslie Teso-Lichtman is an accomplished Senior Executive, Consultant, and Board Member with more than 35 years of success in the medical device, global biotech, and healthcare industries. Leveraging extensive experience with implementing systems, structures and financial controls for start-ups, Leslie is a valuable asset for start-ups seeking guidance on different financing vehicles for fundraising, due diligence, and negotiating the financial aspects of the business.
Throughout her executive career, Leslie has held leadership positions with Insulet Corporation; Roche Diagnostics Hematology, Inc. (formerly Constitution Medical Investors, Inc.); Hologic (formerly Cytyc Corporation); Matritech Inc., and Chas F Thackray USA.
Leslie holds an MBA from Southern New Hampshire University (formerly New Hampshire College); a BS in Business Management, and an AS in Accounting, both from Daniel Webster College. As a seasoned Board Member, she currently serves as a Member, Board of Trustees, Chair Audit & Compliance, Member Finance & Compensation Committees for Atrius Health.